Mainz BioMed NV Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany

BERKELEY, Calif. and MAINZ, Germany, April 04, 2023 (GLOBE NEWSWIRE) — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that three German-based companies have selected ColoAlert®, the Company’s highly efficacious and easy-to-use screening test for colorectal cancer (CRC) into their respective corporate health programs. “At Mainz Biomed, we believe that everyone should have access to colorectal cancer screening, since almost 73,000 cases of colorectal cancer are diagnosed annually in Germany,” said Guido Baechler, Chief Executive Officer of Mainz Biomed. “Including ColoAlert in corporate health programs…